BIA Networking Lunch - Oxford
Join us in Oxford for another BIA networking lunch.
This a great opportunity to network with colleagues, meet new contacts and hear from local BIA members, all whilst enjoying lunch!
11:00 Brexit-focused session with the Office for Life Sciences
12.00: Lunch and networking
13.00: Steve Bates, CEO, BIA
13.10: Update from Oxford Science Park
13.20: Company presentations
14.00: Networking - tea, coffee, and biscuits provided
The Oxford Science Park
Robert Robinson Avenue
Oxford OX4 4GA
I joined Immunocore as Chief Commercial Officer in October 2017 to bring the innovative and transformational science at Immunocore to market. Having stepped into the role of CEO in February 2018, I am delighted to lead the vision for one of the UK’s top biotechnology companies. With more than 30 years of experience in the pharmaceutical sector, I have held numerous cross-functional roles spanning sales, marketing, commercial strategy, country management and regional leadership with Eli Lilly & Co. Additionally, having worked in roles that encompass corporate strategy and business development, I can bring a wealth of knowledge and experience to the BIA Board and continue to help move the BIA in its forward trajectory.
At Lilly, I served in a number of global leadership positions across multiple therapeutic areas and geographies including as Vice President International Business Unit Leader Oncology, President Biomedicines Business Unit, Australia, Canada and Europe and Snr VP Digital Ventures as regional head and country head of a company with commercial, manufacturing and research presence. I represented the company directly with governments across multiple countries so I have a deep understanding of the policy and operational challenges faced by the industry. I have also served as Chairman of the European Markets Committee at EFPIA. I was on the Board of the ABPI for over 6 years and was also Chair of the American Pharma Group.
A science and business park specialist, Piers is the Science Park's Chief Executive, responsible for leading the on-site team, asset management and the ambitious development plans. Piers is a qualified chartered surveyor with over 20 years’ experience in development and asset management. A former Director at Arlington, then Goodman, Piers was responsible for the development of Uxbridge Business Park (with significant HQ lettings to Bristol-Myers Squibb and Amgen), the acquisition and development of Colworth Science Park and Harwell Oxford, and then an ambitious development programme in France, Spain and Germany. More recently, he has been involved in a niche UK Science Park start-up company. Piers began his career at GVA in London.
Dr Ali Jazayeri
Ali Jazayeri joined OMass Therapeutics in October 2018. He was previously Chief Technology Officer of Heptares Therapeutics, a company he joined in 2007 as one of the first scientists and was involved in the transfer of the GPCR stabilisation technology from the MRC Laboratory of Molecular Biology to Heptares. Following successful implementation and industrialisation of the original technology, he led the development of novel methodologies that significantly increased the efficiency and reach of the technology and resulted in the generation of novel IP. In addition, he was one of the key members of the executive sub-team that lead the acquisition of G7 therapeutics, spin out company from University of Zurich and went on to lead the further development and integration of their technology as part of the Heptares Zurich management team. Prior to Heptares, Ali worked as a post-doctoral scientist in Clare Hall Laboratories (a Cancer Research UK institute) and Kudos Pharmaceuticals (later acquired by AstraZeneca) where he carried out research on the role of cell cycle checkpoint kinases in DNA damage response pathways. He has a BSc in Genetics from University of Manchester and obtained his PhD in molecular biology with Prof Steve Jackson at the Gurdon Institute from University of Cambridge.
Free for members and non-members
By registering to this event you accept our Terms & Conditions